文献速递颈动脉与弓上血管

氯吡格雷疗程对颈动脉支架内再狭窄的影响

The Effects of Clopidogrel Duration on Carotid Artery In-Stent Restenosis.
PubMed 文献 · Ann Vasc Surg · 2024-02-11

回顾性分析1996至2016年本机构279例颈动脉支架置入术患者,按氯吡格雷疗程分为短期(<6周,n=159)与长期(>6周,n=112)两组。5年内两组支架内再狭窄总发生率无显著差异(5.03% vs 9.24%,P=0.168),1年、2年、5年随访各时间点亦无显著差异。作者认为无其他长期氯吡格雷指征的患者可考虑缩短双联抗血小板疗程。

要点

  • 短期与长期氯吡格雷组5年内支架内再狭窄总发生率无显著差异(5.03% vs 9.24%,P=0.168)。
  • 1年、2年、5年各随访时间点两组再狭窄率均无显著差异。
  • 作者认为无其他长期氯吡格雷指征者,颈动脉支架术后可考虑较短疗程双联抗血小板治疗。

核心结论

  • 颈动脉支架置入术后短期与长期氯吡格雷治疗在支架内再狭窄发生率上无统计学显著差异。
  • 作者认为,无其他需要延长氯吡格雷治疗指征的患者,颈动脉支架术后可考虑较短疗程的双联抗血小板治疗。

研究设计与样本

  • 回顾性分析本机构20年期间(1996-2016年)所有接受颈动脉支架置入术的患者,共279例。
  • 排除未完成随访双功能超声检查或出院时未使用氯吡格雷的患者。
  • 按氯吡格雷疗程分为短期(<6周,n=159)与长期(>6周,n=112)两组。
  • 临床显著支架内再狭窄定义为:有症状患者再狭窄>50%(收缩期峰值流速=224 cm/s),无症状患者再狭窄>80%(收缩期峰值流速=325 cm/s),依据已发表的流速标准。
  • 采用卡方分析比较两组1年、2年、5年支架内再狭窄率。

主要发现

  • 短期氯吡格雷组较长期组更常有房颤病史(9.43% vs 1.68%,P=0.008)。
  • 短期氯吡格雷组较长期组更少有冠状动脉旁路移植史(16.35% vs 29.41%,P=0.009)、糖尿病史(33.34% vs 49.58%,P=0.006)和冠心病史(50.31% vs 63.03%,P=0.035)。
  • 所有患者均长期服用阿司匹林。
  • 指数手术后5年内两组支架内再狭窄总发生率无显著差异(5.03% vs 9.24%,P=0.168)。
  • 1年(5.61% vs 3%,P=0.321)、2年(2.02% vs 6.59%,P=0.072)、5年(2.24% vs 3.57%,P=0.635)随访时两组再狭窄率亦无显著差异。

临床怎么用

  • 作者认为,无其他需要延长氯吡格雷治疗指征的患者,颈动脉支架置入术后可考虑较短疗程的双联抗血小板治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There are limited data supporting a specific duration for dual antiplatelet therapy in carotid artery stenting (CAS), and most clinical evidence is derived from studies involving coronary interventions. As a result, the appropriate duration of dual antiplatelet therapy after CAS is yet to be determined. We aimed to elucidate whether the duration of dual antiplatelet therapy played a role in the rate of carotid in-stent restenosis. METHODS: A retrospective analysis of all patients who underwent CAS at our institution over a 20-year period (1996-2016) was performed (n = 279). Patients who did not complete their follow-up duplex studies or were not discharged on clopidogrel were excluded from the study. Patients were separated into short-term (<6 weeks, n = 159) and long-term (>6 weeks, n = 112) clopidogrel users based on duration of therapy. We defined clinically significant in-stent restenosis as >50% restenosis (peak systolic velocity = 224 cm/s) in symptomatic patients and >80% restenosis (peak systolic velocity = 325 cm/s) in asymptomatic patients status-post prior CAS based on published velocity criteria. Rates of in-stent restenosis at 1-year, 2-year, and 5-year intervals were analyzed between the 2 groups using chi-squared analysis. RESULTS: Demographic information was largely similar between the 2 groups; however, short-term clopidogrel users were more likely to have a history of atrial fibrillation (9.43% vs. 1.68%, P = 0.008) and were less likely to have a history of coronary artery bypass graft (16.35% vs. 29.41%, P = 0.009), diabetes (33.34% vs. 49.58%, P = 0.006), and coronary artery disease (50.31% vs. 63.03%, P = 0.035). All patients were on long-term aspirin therapy. There was no significant difference between overall rates of in-stent restenosis between the short-term and long-term clopidogrel users (5.03% vs. 9.24%, P = 0.168) within 5 years of the index procedure. Similar results were observed when these groups were evaluated at 1-year (5.61% vs. 3%, P = 0.321), 2-year (2.02% vs. 6.59%, P = 0.072), and 5-year (2.24% vs. 3.57%, P = 0.635) follow-up. CONCLUSIONS: No statistically significant difference was observed in the rate of in-stent restenosis after CAS between short-term and long-term clopidogrel therapy. Patients in whom there is no other indication for longer duration clopidogrel therapy may be considered for shorter duration course of dual antiplatelet therapy following CAS.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Nguyen T, Jokisch C, Dargan C, et al. The Effects of Clopidogrel Duration on Carotid Artery In-Stent Restenosis. Ann Vasc Surg. 2024. PMID: 38350539. doi:10.1016/j.avsg.2023.12.064

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。